cancer
Conditions
Interventions
1 day, 1 time
Sponsors
Okayama University Graduate Shool of Medicine, Dentistry and Pharmaceutical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients who have a target lesion for which pathological diagnosis is required 2) patients with platelet count > 30,000/mm3 3) patients with PT-INR < 1.5 4) patients of 20-years-old or older 5) patients for whom informed consent is obtained 6) patients with a target lesion of at least 10-mm in diameter 7) patients with needle insertion length < 11 cm
Exclusion criteria
Exclusion criteria: 1) patients who cannot limit body motion or hold their breath 2) patients whose needle tract for a target lesion is near (<10 mm) organs at risk such as the heart and aorta, gastrointestinal tract, pancreas, etc 3) patients who cannot stop antiplatelet or anticoagulant agents 4) patients who cannot undergo anesthesia 5) patients whose target lesion is in the head and neck, central nerve system, spinal cord, heart or aorta, and gastrointestinal tract 6) patients in whom the bone is an obstacle in needle tract 7) patients who undergo biopsy with other methods during study period 8) patients who undergo invasive therapy including chemotherapy, radiation, and surgery during study period 9) patients with mental disorder under treatment 10) pregnant patients 11) patients whom a physician judgesto be inappropriate 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of CT fluoroscopy-guided biopsy with Zerobot, which is evaluated by inserting a biopsy introducer needle into the lesion or near the lesion on CT images | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of CT fluoroscopy-guided biopsy with Zerobot, which is evaluated by adverse events and machine trouble of throbot | — |
Countries
Japan
Contacts
Public ContactTako Hiraki
Okayama University Graduate Shool of Medicine, Dentistry and Pharmaceutical Sciences Department of Radiology
Outcome results
None listed